Business
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s third major pharma collaboration within the past 12 months and reflects strong validation of the OGAP®-Verify platform's potential to drive oncology innovationOBT to receive an upfront payment and may be eligible to receive milestone payments, as well as royalties on net sales Oxford, UK and San Jose
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"Oxford BioTherapeutics","displaySize":"","headline":null,"caption":"Oxford BioTherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/1099ab8a5327bbc6a016fb7010fb4c6e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S6S4CXvNkVzlG8DA3GGAWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MQ--/https://media.zenfs.com/en/globenewswire.com/1099ab8a5327bbc6a016fb7010fb4c6e","width":300,"height":115}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets ","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"This is OBT’s third major pharma collaboration within the past 12 months and reflects strong validation of the OGAP®-Verify platform's potential to drive oncology innovation","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"OBT to receive an upfront payment and may be eligible to receive milestone payments, as well as royalties on net sales ","length":118,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":483,"olType":false},{"type":"text","content":"Oxford, UK and San Jose, California, 9 April 2026 – Oxford BioTherapeutics (“OBT”), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP®-Verify platform today announced a multi-year, selective target collaboration with Bristol Myers Squibb (NYSE: BMY, “BMS”) focussed on the discovery and development of novel T-cell engager therapies for solid tumours.","length":473,"tagName":"p"},{"type":"text","content":"OBT will leverage its proprietary OGAP®-Verify target discovery and validation platform, to identify novel, tumour-selective targets for solid cancers and generate next-generation T-cell engager molecules. The collaboration extends beyond discovery, with OBT assuming responsibility for the design and delivery of development candidates, highlighting the company’s expanding evolution into a fully integrated discovery and preclinical development platform. Subsequent research, development and commercialisation activities for these targets ...